Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis.

ABSTRACT: Bortezomib-based regimens are widely used as induction therapy for multiple myeloma (MM). Unlike lenalidomide, the role of bortezomib in consolidation and maintenance therapy for MM is less clear. We performed a meta-analysis to evaluate the impact of bortezomib-based consolidation and maintenance therapy on survival outcomes and adverse events. PubMed, Web of Science, Embase databases, and major conference proceedings were searched for randomized controlled trials (RCTs) of bortezomib-based regimens as consolidation or maintenance therapy for MM. Ten RCTs enrolling 3147 patients were included in the meta-analysis. Bortezomib-based regimens were compared with regimens without bortezomib or observation. The meta-analysis suggested that bortezomib-based maintenance therapy improved progression-free survival (PFS; hazard ratio [HR]?=?0.72, 95% CI 0.55-0.95, P?=?0.02) and overall survival (OS; HR?=?0.71, 95% CI 0.58-0.87, P?=?0.001). Bortezomib-based consolidation therapy improved PFS (HR?=?0.77, 95% CI 0.68-0.88, P?

SUBMITTER: Zhang S 

PROVIDER: S-EPMC7060191 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature